ループス腎炎に対するアフェレシス(<特集>腎疾患とアフェレシス-最近の知見-)

概要

論文の詳細を見る
Systemic lupus erythematosus is a multi-system inflammatory connective tissue disease and characterized by autoantibody production against both nuclear and cytoplasmic cellular antigen. Lupus nephritis is one of the organ complications of SLE but most frequent and severe. Despite great improvement in survival over the past years due to immunosuppressive therapy renal failure remains an important cause of morbidity and mortality. In view of the pathogenesis of lupus nephritis, apheresis, which removes the immune-complex or autoantibody or cytokine, seems rational. Recent controlled studies could not demonstrate the benefit of apheresis which was added to the conventional therapy or not, but there might be a role in individual lupus nephritis patients who are resistant to conventional therapy or with specific situations for which its efficacy has been established to add apheresis (e.g., TTP, APS, cryogloburinemia). When we treat severe lupus nephritis patients with conventional therapy, we should always think whether apheresis should be added or not.
2011-05-31